ScanSource (SCSC) Q2 2026 earnings review
Sales Growth Returns, But Profitability Cracks
ScanSource snapped a year-long streak of revenue declines with a 2.5% YoY increase in Q2, driven by North American hardware demand. However, this volume recovery came at a steep price: Adjusted EBITDA fell 12% as margins compressed due to SG&A investments and gross margin pressure. Consequently, management slashed full-year guidance for both Revenue and EBITDA, signaling that the second-half recovery will be significantly weaker than previously forecasted.
🐂 Bull Case
Recurring revenue grew 16% YoY to $42M, now representing 37.2% of total gross profit (up from 32.5% a year ago). This shift validates the 'hybrid distribution' strategy and builds a more predictable earnings base.
Despite earnings pressure, cash generation remains robust. YTD Free Cash Flow is $49.7M, and the company maintains a net debt leverage of just 0.1x, providing ample capacity for M&A or buybacks.
🐻 Bear Case
Specialty Technology Solutions (STS) grew sales 2.5%, yet its Adjusted EBITDA collapsed 18%. Rising SG&A expenses are currently consuming all gross profit gains, raising questions about the efficiency of recent investments.
Management lowered the FY26 sales ceiling from $3.3B to $3.1B and EBITDA from $160M to $150M. This implies the 'second-half acceleration' narrative from Q1 has largely evaporated.
⚖️ Verdict: 🔴
Bearish. While top-line stabilization is welcome, the deterioration in profitability and the cut to full-year guidance undermine the recovery narrative. The company is spending more to generate less profit than a year ago.
Key Themes
Specialty Tech Profitability Erosion
The core STS segment showed a concerning disconnect: Sales rose 2.5% to $741M, but Adjusted EBITDA fell 18% to $20.9M. The segment's EBITDA margin compressed to 2.8% from 3.5% a year ago, driven by higher SG&A investments that have yet to yield operating leverage.
Gross Margin Compression
Consolidated gross margin fell 18bps YoY to 13.4%. While recurring revenue (98%+ margin) is growing, the hardware product mix or pricing pressure in STS (margin dropped from 10.8% in 25Q2 to 10.5% in 26Q2) is dragging down the consolidated average.
Recurring Revenue Acceleration
Recurring revenue continues to outperform, growing 15.9% YoY driven by Intelisys and cloud services. It now accounts for 37.2% of total Gross Profit, providing a critical buffer against hardware volatility.
Intelisys & Advisory Stability
The I&A segment appears to have stabilized. Net sales grew 3.1% and Adjusted EBITDA grew 4% YoY. While growth is modest, it marks a reversal from the competitive pressures cited in FY25, suggesting recent investments in partner support are beginning to gain traction.
Brazil Weakness
International weakness persists. Brazil net sales (Non-GAAP) fell 9.4% YoY to $54.7M. While a small portion of total revenue, this drag partially offsets the recovery seen in the North American hardware business.
Other KPIs
Decelerating. Down 11.6% YoY. The decline contrasts sharply with the 12% *growth* seen just a quarter ago (26Q1), indicating a rapid shift in expense structure or margin profile.
Stable/Positive. Up 45% vs $34.3M in the prior year period. Operating cash flow remains healthy at $54.1M, supporting the company's ability to fund buybacks ($38.7M YTD).
Decelerating. Down 5.9% YoY from $0.85. The decline was mitigated by share repurchases; Net Income on a dollar basis fell a steeper 14.9%.
Guidance
Decelerating. Cut from prior range of $3.1-$3.3B. The new range midpoint ($3.05B) implies roughly flat growth vs FY25 ($3.04B), erasing hopes for a robust growth year.
Decelerating. Cut from prior range of $150-$160M. The new midpoint ($145M) is essentially flat vs FY25 ($144.7M), despite the company's investments in growth initiatives.
Stable. Maintained from prior guidance. With ~$50M generated in H1, the company needs ~$30M in H2, which appears highly achievable given historical seasonality.
Key Questions
Expense Discipline vs. Growth
SG&A expenses rose 6% YoY while gross profit only rose 1%, crushing operating leverage. When will the 'investments' in Intelisys and STS yield revenue sufficient to cover this increased cost base?
STS Margin Compression
Specialty Tech EBITDA margins dropped to 2.8%, the lowest level in five quarters. Is this driven by competitive pricing pressure in hardware, or purely by discretionary OPEX that can be dialed back?
Guidance Methodology
Revenue guidance was cut significantly ($150M at the midpoint). Does this reflect project cancellations in H2, or was the original guidance reliant on large deals that have pushed out to FY27?